We are live on ! Find out more
VP

venBio Partners Portfolio holdings

AUM $519M
1-Year Est. Return 339.42%
This Fund
S&P 500
This Quarter Est. Return
+137.87%
1 Year Est. Return
+339.42%
3 Year Est. Return
+563.8%
5 Year Est. Return
+1,003.88%
10 Year Est. Return
–
AUM
$667M
AUM Growth
+$315M
Cap. Flow
-$13.1M
Cap. Flow %
-1.96%
Top 10 Hldgs %
100%
Holding
8
New
–
Increased
1
Reduced
–
Closed
1

Top Buys

Rank Stock Value
1
PHVS icon
Pharvaris
PHVS
+$13.3M

Top Sells

Rank Stock Value
1
VTYX
Ventyx Biosciences
VTYX
+$26.4M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RYZB
1
DELISTED
RayzeBio, Inc. Common Stock
RYZB
$321M 48.06%
5,158,162
– –
ALXO icon
2
ALX Oncology
ALXO
$278M
$144M 21.65%
9,699,925
– –
PHVS icon
3
Pharvaris
PHVS
$2.47B
$138M 20.68%
4,919,504
+654,832
+15% +$13.3M
HRMY icon
4
Harmony Biosciences
HRMY
$2.46B
$33.4M 5.01%
1,035,396
– –
SLRN
5
DELISTED
ACELYRIN
SLRN
$28.7M 4.31%
3,852,470
– –
ELEV
6
DELISTED
Elevation Oncology
ELEV
$1.56M 0.23%
2,914,255
– –
IMPL
7
DELISTED
Impel Pharmaceuticals Inc. Common Stock
IMPL
$341K 0.05%
2,759,791
– –
VTYX
8
DELISTED
Ventyx Biosciences
VTYX
– –
-758,800
Closed -$26.4M

Similar funds

CFA
Churchill Financial Advisors Louisville, Kentucky $519M AUM
CFG
Compton Financial Group Towson, Maryland $519M AUM 14.76% 1-Year Est. Return
MWM
Mindset Wealth Management Indianapolis, Indiana $519M AUM 46.03% 1-Year Est. Return
SWM
Scissortail Wealth Management Tulsa, Oklahoma $520M AUM 21.73% 1-Year Est. Return
WS
Wendel SE Paris $519M AUM 48.2% 1-Year Est. Return
GS
Gagnon Securities New York $519M AUM 44.91% 1-Year Est. Return
MWC
MBM Wealth Consultants Chesterfield, Missouri $519M AUM 16.88% 1-Year Est. Return
PDIP
Palo Duro Investment Partners Chicago, Illinois $518M AUM 22.62% 1-Year Est. Return

venBio Partners's Q4 2023 Portfolio in Review

As of Q4 2023, venBio Partners held 8 positions worth $667M, up 89% from $353M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

venBio Partners's Q4 2023 filing shows 1 increased and 1 closed positions. The largest sale was Ventyx Biosciences, an estimated $26.4M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • venBio Partners added most to Pharvaris in Q4 2023, an estimated $13.3M increase.
  • venBio Partners fully exited Ventyx Biosciences in Q4 2023, selling an estimated $26.4M.
  • venBio Partners's ten largest holdings make up 100% of its $667M portfolio in Q4 2023.
  • venBio Partners opened 0 new positions and closed 1 in Q4 2023.
  • venBio Partners's portfolio value rose 89% quarter-over-quarter to $667M.

Based on venBio Partners's 13F filing for Q4 2023, filed 14 Feb 2024.